Advancements in Research on Non-AR- Signaling Pathways and Targeted Therapies for Castration-Resistant Prostate Cancer

Advancements in Research on Non-AR- Signaling Pathways and Targeted Therapies for Castration-Resistant Prostate Cancer

Prostate cancer (Pca) is a significant malignancy affecting men's health, with its incidence steadily increasing worldwide in recent years. Among its various subtypes, castration-resistant prostate cancer (CRPC) holds particular importance due to its pivotal role in the progression and manageme...

Full description

Saved in:

Bibliographic Details
Main Authors:	Haq Dad, Asger Hansen
Format:	Article
Language:	English
Published:	Asian Medical Press Ltd.(H.K.) 2025-01-01
Series:	Annals of Urologic Oncology
Subjects:	prostate cancer androgen receptor signal transduction castration-resistant prostate cancer
Online Access:	http://auo.asmepress.com/articles/new-93-620.html
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The correlation between the expression of androgen receptor splice variant-7 (AR-V7) protein with the time of occurrence of castration-resistant prostate cancer and overall survival in prostate cancer in Indonesian population
by: Indrawarman Soerohardjo, et al.
Published: (2025-02-01)

Meta-analyses of mouse and human prostate single-cell transcriptomes reveal widespread epithelial plasticity in tissue regression, regeneration, and cancer
by: Luis Aparicio, et al.
Published: (2025-01-01)

Sideroflexin family genes were dysregulated and associated with tumor progression in prostate cancers
by: Hua Huang, et al.
Published: (2025-02-01)

AR and YAP crosstalk: impacts on therapeutic strategies in prostate cancer
by: Guansong Zheng, et al.
Published: (2025-02-01)

An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer
by: Yi Wu, et al.
Published: (2025-01-01)

Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer
by: Jong-Lyul Park, et al.
Published: (2018-09-01)

Novel hormonal agents in men with metastatic castration resistant prostate cancer and reduced performance status: Experiences of a specialized single center
by: Thomas Büttner, et al.
Published: (2024-12-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Microbially produced imidazole propionate impairs prostate cancer progression through PDZK1
by: Shengkai Jin, et al.
Published: (2025-01-01)

Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
by: P. G. Berezin, et al.
Published: (2023-09-01)

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)

Long-term ultrasonographic changes of the canine prostate gland after castration
by: Stefano Spada, et al.
Published: (2025-01-01)

Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study
by: Giuseppe Salfi, et al.
Published: (2025-01-01)

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
by: Aaron R. Hansen, et al.
Published: (2025-01-01)

A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer
by: Xiannan Meng, et al.
Published: (2025-01-01)

Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance
by: Caihong Li, et al.
Published: (2025-02-01)

Comprehensive analysis of the interaction microbiome and prostate cancer: an initial exploration from multi-cohort metagenome and GWAS studies
by: Gui-Chen Ye, et al.
Published: (2025-01-01)

Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study
by: Antti Rannikko, et al.
Published: (2025-01-01)

Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer
by: Ayodeji Folorunsho Ajayi, et al.
Published: (2025-02-01)

Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer
by: Alacia M. Voth, et al.
Published: (2017-05-01)

Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer
by: Maurizio Capuozzo, et al.
Published: (2024-05-01)

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
by: Zixi Wu, et al.
Published: (2025-12-01)

Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study
by: Jae Heon Kim, et al.
Published: (2025-01-01)

Alleviatory effect of isoquercetin on benign prostatic hyperplasia via IGF-1/PI3K/Akt/mTOR pathway
by: Young-Jin Choi, et al.
Published: (2024-05-01)

ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy
by: Agathe Bessot, et al.
Published: (2025-02-01)

The 340B Drug Pricing Program and Management of Advanced Prostate Cancer
by: Kassem S. Faraj, et al.
Published: (2025-01-01)

Elucidating the role of pyrimidine metabolism in prostate cancer and its therapeutic implications
by: Liang Huang, et al.
Published: (2025-01-01)

Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients
by: Yahia Ghazwani, et al.
Published: (2025-01-01)

Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis
by: Amir Alinejad Khorram, et al.
Published: (2024-12-01)

The factors impacting on Gleason score upgrading in prostate cancer with initial low Gleason scores
by: Tzu-Heng Huang, et al.
Published: (2025-02-01)

Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen
by: Zh. R. Cherkasova, et al.
Published: (2023-03-01)

Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer
by: Xiang Pan, et al.
Published: (2025-01-01)

A partial differential equation model of metastasized prostatic cancer
by: Avner Friedman, et al.
Published: (2013-03-01)

Association between prostate-specific antigen density and prostate cancer prediction among Nigerian men
by: Abudu EK, et al.
Published: (2025-01-01)

Enhancing in Vitro anti-metastatic efficacy and deep penetration into tumor spheroid of docetaxel-loaded liposomes via size optimization for prostate cancer treatment
by: Saksorn Klibaim, et al.
Published: (2025-03-01)

Extracellular Vesicles and Tunnelling Nanotubes as Mediators of Prostate Cancer Intercellular Communication
by: Jessica K. Heatlie, et al.
Published: (2024-12-01)

Inhibiting HnRNP L-mediated alternative splicing of EIF4G1 counteracts immune checkpoint blockade resistance in Castration-resistant prostate Cancer
by: Xumin Zhou, et al.
Published: (2025-02-01)

The Novel Histological Prostatic Inflammation Score Helps Defining the Association Between Stromal and Glandular Inflammation with the Risk of Prostate Cancer at Prostate Biopsy
by: Ugo Giovanni Falagario, et al.
Published: (2025-01-01)

Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01)

A Rare Metastasis of Prostate Cancer
by: İlkin Hamid-Zada, et al.
Published: (2024-07-01)